HOCPF:OTC-HOYA Corporation (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 123.1

Change

0.00 (0.00)%

Market Cap

USD 43.50B

Volume

938.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-18 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOF EssilorLuxottica Société ano..

N/A

USD 104.77B
ESLOY Essilor International SA

N/A

USD 104.51B
HOCPY Hoya Corp

N/A

USD 41.61B
RSMDF Resmed Inc DRC

N/A

USD 31.08B
CLPBY Coloplast A

N/A

USD 27.81B
CLPBF Coloplast A/S

N/A

USD 27.53B
TRUMF Terumo Corporation

N/A

USD 25.47B
TRUMY Terumo Corp ADR

N/A

USD 25.37B
SAUHY Straumann Holding AG ADR

N/A

USD 20.74B
SRTOY Sartorius Stedim Biotech S.A

N/A

USD 20.68B

ETFs Containing HOCPF

DBJP Xtrackers MSCI Japan Hedg.. 0.00 % 0.47 %

N/A

USD 0.42B
DXJH 0.00 % 0.48 %

N/A

N/A
EWJ iShares MSCI Japan ETF 0.00 % 0.47 %

N/A

USD 16.28B
FLJH Franklin FTSE Japan Hedge.. 0.00 % 0.09 %

N/A

USD 0.06B
FLJP Franklin FTSE Japan ETF 0.00 % 0.09 %

N/A

USD 2.06B
CSJP:LSE iShares VII PLC - iShares.. 0.00 % 0.00 %

N/A

USD 0.62B
HMJD:LSE HSBC ETFs Public Limited .. 0.00 % 0.00 %

N/A

USD 0.19B
HMJP:LSE HSBC MSCI JAPAN UCITS ETF 0.00 % 0.00 %

N/A

USD 0.19B
IJPA:LSE iShares Core MSCI Japan I.. 0.00 % 0.00 %

N/A

USD 3.63B
IJPD:LSE iShares Public Limited Co.. 0.00 % 0.00 %

N/A

USD 0.43B
IJPE:LSE iShares MSCI Japan EUR He.. 0.00 % 0.00 %

N/A

USD 0.72B
IJPN:LSE iShares MSCI Japan UCITS .. 0.00 % 0.00 %

N/A

USD 1.11B
IJPU:LSE iShares MSCI Japan UCITS .. 0.00 % 0.00 %

N/A

USD 1.11B
JPEH:LSE SPDR® MSCI Japan EUR Hdg.. 0.00 % 0.00 %

N/A

USD 0.04B
JPJP:LSE SPDR® MSCI Japan UCITS E.. 0.00 % 0.00 %

N/A

USD 77.76B
JPXG:LSE 0.00 % 0.00 %

N/A

N/A
JPXU:LSE Lyxor UCITS JPX-Nikkei 40.. 0.00 % 0.00 %

N/A

USD 0.01B
JPXX:LSE Lyxor UCITS JPX-Nikkei 40.. 0.00 % 0.00 %

N/A

USD 9.86M
LCJD:LSE Amundi MSCI Japan (DR) UC.. 0.00 % 0.00 %

N/A

USD 650.46B
LCJG:LSE Lyxor Core MSCI Japan (DR.. 0.00 % 0.00 %

N/A

USD 0.04B
LCJP:LSE Lyxor Core MSCI Japan (DR.. 0.00 % 0.00 %

N/A

USD 652.47B
SJPA:LSE iShares Core MSCI Japan I.. 0.00 % 0.00 %

N/A

USD 5.62B
IJPH:LSE iShares MSCI Japan GBP He.. 0.00 % 0.00 %

N/A

USD 0.12B
UB02:LSE UBS MSCI Japan UCITS JPY .. 0.00 % 0.00 %

N/A

USD 117.12B
UB0D:LSE UBS(Lux)Fund Solutions .. 0.00 % 0.00 %

N/A

USD 0.10B
UC65:LSE UBS (Lux) Fund Solutions .. 0.00 % 0.00 %

N/A

USD 116.66B
XDNG:LSE db x-trackers JPX-Nikkei .. 0.00 % 0.00 %

N/A

USD 0.01B
XDNS:LSE Xtrackers MSCI Japan ESG .. 0.00 % 0.00 %

N/A

USD 56.72B
XDNU:LSE db x-trackers JPX-Nikkei .. 0.00 % 0.00 %

N/A

USD 2.07M
XDNY:LSE Xtrackers MSCI Japan ESG .. 0.00 % 0.00 %

N/A

USD 56.72B
XMJD:LSE Xtrackers - MSCI Japan UC.. 0.00 % 0.00 %

N/A

USD 2.30B
XMJG:LSE 0.00 % 0.00 %

N/A

N/A
XMJP:LSE Xtrackers MSCI Japan UCIT.. 0.00 % 0.00 %

N/A

USD 2.30B
XMUJ:LSE Xtrackers - MSCI Japan UC.. 0.00 % 0.00 %

N/A

USD 0.03B
UB0C:LSE 0.00 % 0.00 %

N/A

N/A
CJPU:LSE iShares VII PLC - iShares.. 0.00 % 0.00 %

N/A

USD 0.62B
SAJP:LSE iShares MSCI Japan ESG Sc.. 0.00 % 0.00 %

N/A

USD 1.47B
SDJP:LSE iShares MSCI Japan ESG Sc.. 0.00 % 0.00 %

N/A

USD 0.49B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.42% 74% C 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.42% 68% D+ 62% D
Trailing 12 Months  
Capital Gain 4.28% 75% C 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.28% 73% C 60% D-
Trailing 5 Years  
Capital Gain 69.44% 86% B+ 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.44% 80% B- 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 11.62% 60% D- 58% F
Dividend Return 11.62% 52% F 54% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.16% 81% B- 76% C+
Risk Adjusted Return 42.79% 85% B 81% B-
Market Capitalization 43.50B 96% N/A 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector